Barcelona, Spain

Marc Centellas Casado



 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Marc Centellas Casado

Introduction

Marc Centellas Casado is a prominent inventor based in Barcelona, Spain. He has made significant contributions to the field of biotechnology, particularly in the treatment of transthyretin-associated amyloidosis. With a total of 5 patents to his name, his work is paving the way for advancements in medical therapies.

Latest Patents

One of Marc's latest patents focuses on a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. This innovative therapy not only addresses the condition directly but also explores the potential of combination therapy with other agents such as benzoxazole derivatives, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate. His research aims to enhance the efficacy of treatments for this challenging disease.

Career Highlights

Marc is currently associated with Som Innovation Biotech, S.L., where he continues to develop groundbreaking therapies. His dedication to research and innovation has positioned him as a key figure in the biotechnology sector.

Collaborations

Throughout his career, Marc has collaborated with notable professionals in the field, including Raúl Insa Boronat and Nuria Reig Bolaño. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions.

Conclusion

Marc Centellas Casado's contributions to biotechnology, particularly in the treatment of transthyretin-associated amyloidosis, highlight his role as a leading inventor. His ongoing work promises to bring new hope to patients affected by this condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…